orforglipron and retatrutide Eli Lilly Company's triple agonist, retatrutide, successful in two additional phase 3 obesity trials, delivering significant improvements in weight and A1C Retatrutide vs Orforglipron: Efficacy vs

2024 Jun 26;13(13):3729)

Medical Weight Loss Programs: Integrating L-Carnitine injections into a medical weight loss plan can boost fat metabolism and energy levels, complementing the effects of diet and exercise

Combined L-citrulline supplementation and slow velocity low-intensity resistance training improves leg endothelial function, lean mass, and strength in hypertensive postmenopausal women

Other Possible Serious or Concerning Side Effects Although rare, some studies have reported more serious or unusual adverse events, including: Cardiac arrhythmia Elevated liver enzymes Acute pancreatitis (rare cases) Abnormal skin sensations (dysesthesia) in some trials Because the drug affects several hormone pathways involved in metabolism, researchers say long-term safety data will be essential before approval